Search

Your search keyword '"Teti, E."' showing total 26 results

Search Constraints

Start Over You searched for: Author "Teti, E." Remove constraint Author: "Teti, E." Database Unpaywall Remove constraint Database: Unpaywall
26 results on '"Teti, E."'

Search Results

1. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

2. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

3. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

4. Whole-brain white matter network reorganization in HIV

5. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

6. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

7. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

8. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

9. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?

10. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

11. Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy

12. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

13. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

14. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

15. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

17. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

18. Natural HCV resistance is common in Italy and differently associated to genotypes

19. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

20. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

21. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies

22. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment

23. Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program

Catalog

Books, media, physical & digital resources